(Q39970216)

16 September 2017

title

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status (English)

1 reference

16 September 2017

1 reference

Catia Cemeus

1

1 reference

16 September 2017

Tong T Zhao

2

1 reference

16 September 2017

Gordon M Barrett

3

1 reference

16 September 2017

Ian A Lorimer

4

1 reference

16 September 2017

Jim Dimitroulakos

5

1 reference

16 September 2017

publication date

20 June 2008

1 reference

Journal of Neuro-Oncology

16 September 2017

published in

1 reference

16 September 2017

volume

90

1 reference

16 September 2017

issue

1

1 reference

16 September 2017

page(s)

9-17

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-008-9627-0

16 September 2017

exact match

0 references

cites work

Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Epidemiology and molecular pathology of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

A transient three-plasmid expression system for the production of high titer retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Pharmacology of competitive inhibitors of HMG-CoA reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9627-0

Inhibitors of prenyl transferases.

21 January 2018

1 reference

12 December 2020

Erlotinib (Tarceva): an update on the clinical trial program

1 reference

12 December 2020

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

1 reference

12 December 2020

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

1 reference

12 December 2020

EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions

1 reference

12 December 2020

Epidermal growth factor receptor structure, regulation, mitogenic signalling and effects of activation

1 reference

12 December 2020

Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro

1 reference

12 December 2020

Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin

1 reference

12 December 2020

The statins as anticancer agents

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

1 reference

12 December 2020

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications

1 reference

12 December 2020

HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells

1 reference

12 December 2020

10.1007/S11060-008-9627-0

Identifiers

DOI

1 reference

16 September 2017

1 reference